NAV

Hydracarbazine

Identification

Generic Name
Hydracarbazine
DrugBank Accession Number
DB09243
Background

Hydracarbazine is a pyridazine that has found use as an antihypertensive agent 1 It was once marketed in France under the tradename Normatensyl.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 153.145
Monoisotopic: 153.065059865
Chemical Formula
C5H7N5O
Synonyms
  • Hydracarbazine
External IDs
  • TH-2151
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Was used for the treatment of hypertension 1.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Relaxes vascular smooth muscle 1.

Mechanism of action

Likely acts similarly to hydralazine, a related compound, which interferes with calcium release from the sarcoplasmic reticulum in response to inositol 2.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Hydracarbazine is combined with 1,2-Benzodiazepine.
AbaloparatideHydracarbazine may increase the orthostatic hypotensive activities of Abaloparatide.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Abciximab.
AcarboseHydracarbazine may increase the hypoglycemic activities of Acarbose.
AcebutololHydracarbazine may increase the hypotensive activities of Acebutolol.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 2-heteroaryl carboxamides. These are compounds containing a heteroaromatic ring that carries a carboxamide group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
2-heteroaryl carboxamides
Alternative Parents
Pyridazines and derivatives / Imidolactams / Heteroaromatic compounds / Primary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives / Hydrazines and derivatives
Substituents
2-heteroaryl carboxamide / Aromatic heteromonocyclic compound / Azacycle / Heteroaromatic compound / Hydrazine derivative / Hydrocarbon derivative / Imidolactam / Organic nitrogen compound / Organic oxide / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
6CTK2FB9QM
CAS number
3614-47-9
InChI Key
WRYZEGZNBYOMLE-UHFFFAOYSA-N
InChI
InChI=1S/C5H7N5O/c6-5(11)3-1-2-4(8-7)10-9-3/h1-2H,7H2,(H2,6,11)(H,8,10)
IUPAC Name
6-hydrazinylpyridazine-3-carboxamide
SMILES
[H]N([H])N([H])C1=NN=C(C=C1)C(=O)N([H])[H]

References

General References
  1. Francis JE: Antihypertensives acting by a peripheral mechanism ACS Symposium Series. 1976 June 01;27:55-79. [Article]
  2. 22. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 273). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
PubChem Compound
71653
PubChem Substance
310265146
ChemSpider
64713
ChEBI
136055
ChEMBL
CHEMBL2106246
ZINC
ZINC000005842953
Wikipedia
Hydracarbazine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.3 mg/mLALOGPS
logP-0.95ALOGPS
logP-1Chemaxon
logS-1.2ALOGPS
pKa (Strongest Acidic)13.88Chemaxon
pKa (Strongest Basic)6.03Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area106.92 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity42.49 m3·mol-1Chemaxon
Polarizability14.15 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-115l-8900000000-bd718d40e8993f19c290
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-e8d21bac03ac07d8be72
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-9649e1359bc7aa9158b0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-3900000000-9ff223f983842e8a51b7
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-100u-9300000000-dfb4ea1608cfee74145c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9600000000-e5986ff72c88614c64f3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-232ff2fb4c174ac20657
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-133.9089859
predicted
DarkChem Lite v0.1.0
[M-H]-132.57298
predicted
DeepCCS 1.0 (2019)
[M+H]+134.5541859
predicted
DarkChem Lite v0.1.0
[M+H]+134.96855
predicted
DeepCCS 1.0 (2019)
[M+Na]+134.4921859
predicted
DarkChem Lite v0.1.0
[M+Na]+141.2307
predicted
DeepCCS 1.0 (2019)

Drug created at October 23, 2015 22:06 / Updated at February 21, 2021 18:52